Xellia Pharmaceuticals, which focuses on providing important anti-infective treatments against serious and often life-threatening infections, announced the formation of a new Scientific Advisory Board (SAB).
The SAB brings together leading international scientific and clinical advisors with expertise in infectious diseases, clinical microbiology, respiratory medicines and drug research and development. The SAB Chairman will be Professor George E Griffin, Emeritus Professor of Infectious Disease and Medicine at St George’s, University of London, UK.
Carl-Åke Carlsson, Xellia’s CEO said: “As Xellia has continued to grow, the breadth of our science has increased beyond manufacturing of anti-infective generics to supporting more innovative product developments. We welcome the members of the new Scientific Advisory Board to the company. Their scientific and clinical insight and guidance combined with our specialist expertise will help us improve the efficacy, increase safety profile and reduce the side effects of existing molecules and develop new drugs to help tackle the global crisis of antimicrobial resistance.”